New study tests which chemo combo works best for common breast cancers
NCT ID NCT04193059
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This phase 3 trial compares two chemotherapy regimens for women with non-triple negative breast cancer after surgery. One group gets epirubicin plus cyclophosphamide followed by docetaxel (EC-T), the other gets paclitaxel plus carboplatin (PCb). The study includes 1560 participants and tracks how long they stay cancer-free. It also looks at side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (epirubicin, cyclophosphamide, docetaxel, paclitaxel, carboplatin, and trastuzumab)
What this could lead to
If successful, this could show that a carboplatin-based regimen works as well as or better than standard anthracycline-based chemo for certain breast cancer types, potentially reducing side effects.
What could go wrong
This is a single-center trial, so results may not apply broadly. Chemotherapy has well-known side effects like fatigue, nausea, and increased infection risk. The study is not testing a new drug, just comparing existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.